Fierce Healthcare March 20, 2023
By Robert King

States have been grappling with rising Medicaid drug costs for the past several years. A new report from the Medicaid and CHIP Payment and Access Commission gives some recommendations on how to handle the issue. (Getty/Charles Wollertz)

Congress should give states the power to not pay full price under Medicaid for drugs approved under the Food and Drug Administration’s accelerated approval pathway, a key advisory panel said.

The Medicaid and CHIP Payment and Access Commission (MACPAC) released proposals for Congress as part of its March report last week (PDF). One of the key recommendations is to limit state coverage under Medicaid of drugs cleared via accelerated approval that have not completed a confirmatory trial. The recommendation is...

Today's Sponsors


Today's Sponsor


Topics: Congress / White House, Govt Agencies, Insurance, Medicaid, States, Survey / Study, Trends
CommonSpirit 'doubly concerned' about California Medicaid
Too Little, Too Late: Initial Launch Prices And Access To Cures For Medicaid Enrollees
Shift AI Podcast: Setting AI guidelines at work, with City of Seattle interim CTO, Jim Loter
We Need National Policies For Voice-Based Telepsychiatry
Most states offer Medicare Advantage plans to retired employees: 5 things to know

Share This Article